About GOA Therapeutics
GOA Therapeutics develops drug candidates for alcohol intoxication and poisoning. Its lead candidate, GOA26, is designed to lower blood alcohol concentration quickly. GOA26 came out of protein engineering, formulation and manufacturing work. The company is preclinical and is moving toward an IND filing and clinical studies.
The company is based in West Palm Beach, Florida. Andrew Altschuler is co-founder and chief executive officer, and Tami Ehrmann Barr is co-founder and chief scientist. Dean Hakanson is chief medical officer, and David Landesman is chief operating officer. Scott Howell is chief commercial officer, and Iris Tam is head of medical affairs.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 22, 2026 | Nov 5, 2026 | $300,000of $225.0M target | 1 | $300K | EquityRule 506(c) | Form D ↗ |
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Rounds announced by GOA Therapeutics
What the company said publicly about its funding. Announced amounts can differ from Form D figures: an announcement can combine several closings, and some money is raised without a Form D.
| Announced | Round | Amount | Investors | Source |
|---|---|---|---|---|
| Sep 17, 2026 | Not stated | $15.5 million | BioWorld ↗ Yahoo Finance ↗ |
Why Investors Backed GOA Therapeutics
GOA Therapeutics is a preclinical drug developer in West Palm Beach, Florida. Its lead candidate, GOA26, is aimed at alcohol intoxication and poisoning. The company came out of stealth in September 2026 with $15.5 million in funding, according to BioWorld.
The problem it targets
GOA points to about 178,000 US deaths a year from excessive drinking, citing MMWR and the National Institute on Alcohol Abuse and Alcoholism. It puts yearly US emergency room visits at about 5 million, citing a June 2026 ClearView assessment and its own data. It cites a 2015 study, based on 2010 data, for a yearly economic cost of $249 billion. In GOA's view, the world has come to accept this toll.
What the product does
GOA26 is built to bring blood alcohol concentration down quickly. Its science traces to co-founder Tami Ehrmann Barr, whose research focused on protein engineering, particularly therapeutic enzymes. Chief executive officer Andrew Altschuler told Fierce Biotech the grand vision is an over-the-counter, non-prescription product as widely available as Narcan.
Progress so far
GOA26 came after more than a decade of research and development. It has completed successful IND-enabling testing in porcine models. Fierce Biotech reported that Altschuler said all the alcohol cleared from the animals after treatment with the first generation of her proteins. More than 30 patent filings worldwide cover GOA26. Chief medical officer Dean Hakanson was previously vice president and head of US medical affairs at Gilead Sciences.
Who backs it
BioWorld reported $15.5 million in funding at the September 2026 launch. Founder and chief executive officer Andrew Altschuler has more than 30 years of business experience. He has founded companies in industries including biotechnology, fintech, e-commerce and real estate. Co-founder Tami Ehrmann Barr has held senior science and executive roles in pharmaceuticals, biotechnology and medical devices. Her leadership experience includes Nano Dimension, Can-Fite Biopharma, RDD Pharma and ADAMA.
We wrote this summary from public statements by GOA Therapeutics and its investors. It is not investment advice.
GOA Therapeutics in the News
Leadership Team
Executive officers and directors listed on GOA Therapeutics's Form D filed Nov 5, 2026.
